A “research use only” line in your footer doesn’t make you a research supplier. The FDA has said so in warning letters in February 2025, December 2025, March 2026 and August 2026, and each time the disclaimer was there and the agency looked straight past it.
Research use only website compliance isn’t a sentence you add. It’s whether every page, email, image, review and support reply tells the same story as that sentence. When they don’t, the disclaimer stops being protection and starts looking like evidence you knew what you were doing.
This post covers what research use only actually means for a peptide store, what the FDA has said about it, why a peptide website disclaimer can’t cancel the rest of a site, and how we’d run a whole-business consistency audit.
What the FDA has said about RUO disclaimers
The starting point is a regulation, not a warning letter. Under 21 CFR 201.128, a product’s intended use is judged objectively. It can be shown by “labeling claims, advertising matter, or oral or written statements” and by the circumstances of the sale. In plain terms: the FDA decides what your product is for by looking at how you sell it, not by reading the line you wrote about it.
The warning letters apply that idea again and again:
- USAPeptide.com, February 26, 2025.
- Pinnacle Peptides, December 12, 2025. The labels said “FOR RESEARCH ONLY” and “NOT FOR HUMAN USE,” and FDA still found the products “intended to be drugs for human use.”
- Gram Peptides, March 31, 2026. Despite “Research Use Only” and “not intended for human consumption” labeling, FDA wrote that its evidence “establishes that your products are intended to be drugs for human use.” The firm had 15 working days to respond. (Read the Gram Peptides letter.)
- Pink Pony Peptides, March 31, 2026.
- A batch dated August 24, 2026, to several peptide sellers. Law firm summaries count four or five letters. FDA dismissed the RUO and “not for human consumption” disclaimers, and the evidence it cited was website claims, dosing guidance, peptide reconstitution calculators, “peptide guides,” and bacteriostatic water sold alongside the peptides.
That last detail is the one to sit with. The August letters were based on website review alone. Nobody needed to buy anything or interview anyone. The site was enough.
What research use only means, and where the phrase comes from
The formal wording comes from the in-vitro diagnostic regulation at 21 CFR 809.10(c)(2)(i): “For Research Use Only. Not for use in diagnostic procedures.” It’s a labeling category for diagnostic products, not a safe harbor in drug law that peptide sellers can borrow.
Even label suppliers say this. OnlineLabels’ peptide label guide warns that the RUO statement must actually describe the product, and shouldn’t be added just because other peptide vials carry it.
None of this means an RUO statement is useless. It means it only works when it’s true, and it’s only true when the business behaves that way.
Why a footer disclaimer can’t cancel the rest of the site
Regulators aren’t the only readers who think this way. LegitScript’s October 2025 guide for payment processors on peptides lists a “Not for Human Consumption” disclaimer as a red flag in its own right, alongside no buyer qualification step, lab-style injectable-vial branding and bodybuilding or tanning marketing. Stripe prohibits “Incorrectly labeled research chemicals.” Underwriters, monitoring services and the FDA are all asking one question: does the disclaimer match the behavior?
A typical case: a store has a clean RUO banner on every page, but the blog has a post titled something like “how to reconstitute and store your vials at home,” the product page links to a calculator, and the top review mentions results. Each piece looks small. Together they describe a human-use business with a disclaimer stapled on, which is exactly the pattern in the August 2026 letters.
That’s also why we cover the same ground from the payments side in what underwriters check before approving a peptide store. The review is the same review, just with different consequences.
A research use only website compliance audit, channel by channel
This is the core of the work. Go channel by channel and ask whether each one would survive being read on its own.
| Channel | What to look for | What consistent looks like |
|---|---|---|
| Product pages | Dosing, protocols, “how to use,” effect or benefit words | Name, quantity, purity spec, lot number, storage, batch COA |
| Images | Syringes, people, gym or tanning imagery, before-and-after | Vial, label, packaging, COA, lab or neutral backgrounds |
| Reviews | Any review describing personal use or results | Reviews about shipping, packaging, documentation, or none at all |
| Blog and guides | Human-use guides, reconstitution how-tos, “stacks” | Lab handling, storage conditions, COA reading, company news |
| Tools | Reconstitution or dose calculators | None |
| Bundles and cross-sells | Bacteriostatic water, syringes or kits sold alongside | Catalog limited to what a research buyer needs |
| Emails | Subject lines and flows promising results | Restocks, new batches, COA updates, shipping notices |
| Social and affiliates | Influencer content, personal-use posts, comment replies | The same rules as the site, written into affiliate terms |
| Customer service | Live chat and email answers to “how much should I take?” | A scripted refusal, applied every time |
| Labels and packaging | Missing lot numbers, wording that contradicts the site | Label, site and COA all agree |
| SEO metadata | Page titles, alt text and URLs targeting human-use searches | Titles built on compound names, specs and COAs |
Two rows catch people out. Customer service is where intent leaks out most often, because one helpful agent answering a dosing question in chat undoes a year of careful copywriting. Write the script, train on it, and spot-check transcripts. SEO metadata is the other: a product page can read cleanly while its title tag targets a human-use query. We cover building search traffic without that trap in how to rank a peptide website without medical claims.
Disclaimer placement and wording principles
We’re deliberately not giving you a template to paste. A disclaimer copied from another store is how you end up with wording that doesn’t describe your business, which is the exact problem OnlineLabels warns about. Instead, some principles:
- Say it plainly and say the same thing everywhere. One wording, used on the label, product pages, checkout and terms of sale. Variations look improvised.
- Put it where decisions happen. Near the add-to-cart button and as an acknowledgement at checkout, not only in the footer.
- Back it with process. An age gate, a buyer acknowledgement and, if it fits your customers, a buyer qualification step. LegitScript’s guide notes that “Legitimate sellers will often require a buyer to first contact them.”
- Don’t treat it as magic words. Wording can’t fix a site that contradicts it, so spend more time on the audit above than on the sentence.
- Have counsel review the final language. A lawyer familiar with FDA and FTC rules should sign off on the wording and on how your business is set up to match it.
Building sites this way from the first wireframe is a lot cheaper than retrofitting them, which is why it’s baked into how we approach peptide website design.
What changed in 2026, and what didn’t
A lot of peptide sellers read the 2026 FDA headlines as a loosening. They weren’t.
On April 15, 2026, FDA said it would remove 12 peptides from its Category 2 list after their nominations were withdrawn, and noted that removal “does not, by itself, establish eligibility for compounding.” On July 23 to 24, an advisory committee voted on several peptides for the 503A bulks list. Those votes are advisory; any change needs notice-and-comment rulemaking, and none of these peptides is FDA-approved. Even if rules change, compounding requires pharmaceutical-grade API and a patient-specific prescription. Research-grade product can’t lawfully be used for it.
So nothing in 2026 makes human-use marketing of research product acceptable. The warning letters kept coming through the same period.
How we’d run the audit this week
- Crawl the site and export every URL, title tag and image alt text.
- Search that export, plus product descriptions and blog posts, for dosing language, “protocol,” “cycle,” “stack,” “results,” “before and after” and calculator links.
- Export all reviews and delete or hide any that describe personal use.
- Pull the last 50 support conversations and read them for dosing or use questions, and how they were answered.
- Read every live email flow and the last three months of campaigns.
- Review social accounts and every affiliate’s recent posts.
- Check that the label, product page and COA agree on name, quantity and lot number for your top SKUs.
- Rewrite, remove, retrain. Then pick one wording for the disclaimer and get counsel to review it.
We work with research suppliers who want to run a clean, defensible business, and with clinics and telehealth brands that can qualify for certification. We don’t help anyone dress up human-use sales as research. If you’re a clinic weighing that second route, our LegitScript certification support is where to start.
FAQ
Does a research use only disclaimer protect a peptide website?
Not on its own. FDA warning letters from 2025 and 2026 dismissed RUO and “not for human consumption” disclaimers when the rest of the site pointed to human use, and the August 2026 letters relied on website review alone.
Where should a peptide website disclaimer go?
On product labels, product pages near the add-to-cart button, as an acknowledgement at checkout, and in the terms of sale, using the same wording everywhere. Placement matters less than whether the rest of the site agrees with it.
Can I copy another store’s RUO disclaimer?
We wouldn’t. A copied disclaimer often doesn’t describe your products or how you operate, and label suppliers warn against adding RUO wording just because others use it. Have a lawyer familiar with FDA and FTC rules review your own wording.
Is selling bacteriostatic water with peptides a problem?
FDA cited bacteriostatic water sold alongside peptides as evidence of human-use intent in its August 2026 warning letters. If you sell it, think hard about how it looks next to your catalog, and get legal advice on it.

